Figure S3 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy

作者：Anil P. Bidkar, Sinan Wang, Kondapa Naidu Bobba, Emily Chan, Scott Bidlingmaier, Emily A. Egusa, Robin Peter, Umama Ali, Niranjan Meher, Anju Wadhwa, Suchi Dhrona, Chandrashekhar Dasari, Denis Beckford-Vera, Yang Su, Ryan Tang, Li Zhang, Jiang He, David M. Wilson, Rahul Aggarwal, Henry F. VanBrocklin, Youngho Seo, Jonathan Chou, Bin Liu, Robert R. Flavell · 年份：2025 · DOI：10.1158/1078-0432.30706871 · 研究领域：Radiopharmaceutical Chemistry and Applications、Prostate Cancer Treatment and Research、Immunotherapy and Immune Responses

<p>Figure S3: Binding of [225Ac]DOTA-YS5 to 22Rv1 with or without cold antibody blocking. Blocking with cold YS5 results in a reduction of binding from 19.25±0.70% to 4.46±0.17% (n=3).</p>